China · Delayed Price · Currency is CNY Winner Medical Statistics
Total Valuation
Winner Medical has a market cap or net worth of CNY 17.12 billion. The enterprise value is 15.91 billion.
| Market Cap | 17.12B |
| Enterprise Value | 15.91B |
Important Dates
The last earnings date was Tuesday, October 27, 2026.
| Earnings Date | Oct 27, 2026 |
| Ex-Dividend Date | Sep 2, 2026 |
Share Statistics
Winner Medical has 572.07 million shares outstanding. The number of shares has decreased by -0.55% in one year.
| Current Share Class | 574.92M |
| Shares Outstanding | 572.07M |
| Shares Change (YoY) | -0.55% |
| Shares Change (QoQ) | -1.24% |
| Owned by Insiders (%) | 71.69% |
| Owned by Institutions (%) | 8.04% |
| Float | 163.94M |
Valuation Ratios
The trailing PE ratio is 22.35 and the forward PE ratio is 18.25.
| PE Ratio | 22.35 |
| Forward PE | 18.25 |
| PS Ratio | 1.52 |
| PB Ratio | 1.40 |
| P/TBV Ratio | 1.85 |
| P/FCF Ratio | 22.24 |
| P/OCF Ratio | 11.19 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 8.26, with an EV/FCF ratio of 20.68.
| EV / Earnings | 20.48 |
| EV / Sales | 1.41 |
| EV / EBITDA | 8.26 |
| EV / EBIT | 13.09 |
| EV / FCF | 20.68 |
Financial Position
The company has a current ratio of 1.88, with a Debt / Equity ratio of 0.25.
| Current Ratio | 1.88 |
| Quick Ratio | 1.28 |
| Debt / Equity | 0.25 |
| Debt / EBITDA | 1.61 |
| Debt / FCF | 4.03 |
| Interest Coverage | 34.50 |
Financial Efficiency
Return on equity (ROE) is 6.73% and return on invested capital (ROIC) is 9.89%.
| Return on Equity (ROE) | 6.73% |
| Return on Assets (ROA) | 4.06% |
| Return on Invested Capital (ROIC) | 9.89% |
| Return on Capital Employed (ROCE) | 8.85% |
| Weighted Average Cost of Capital (WACC) | 3.70% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | 15,855 |
| Asset Turnover | 0.60 |
| Inventory Turnover | 2.66 |
Taxes
In the past 12 months, Winner Medical has paid 192.23 million in taxes.
| Income Tax | 192.23M |
| Effective Tax Rate | 18.92% |
Stock Price Statistics
The stock price has decreased by -21.28% in the last 52 weeks. The beta is -0.01, so Winner Medical's price volatility has been lower than the market average.
| Beta (5Y) | -0.01 |
| 52-Week Price Change | -21.28% |
| 50-Day Moving Average | 29.58 |
| 200-Day Moving Average | 31.67 |
| Relative Strength Index (RSI) | 49.56 |
| Average Volume (20 Days) | 3,930,504 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Winner Medical had revenue of CNY 11.25 billion and earned 776.96 million in profits. Earnings per share was 1.34.
| Revenue | 11.25B |
| Gross Profit | 5.26B |
| Operating Income | 1.22B |
| Pretax Income | 1.02B |
| Net Income | 776.96M |
| EBITDA | 1.69B |
| EBIT | 1.22B |
| Earnings Per Share (EPS) | 1.34 |
Balance Sheet
The company has 5.12 billion in cash and 3.10 billion in debt, with a net cash position of 2.03 billion or 3.54 per share.
| Cash & Cash Equivalents | 5.12B |
| Total Debt | 3.10B |
| Net Cash | 2.03B |
| Net Cash Per Share | 3.54 |
| Equity (Book Value) | 12.21B |
| Book Value Per Share | 19.92 |
| Working Capital | 4.58B |
Cash Flow
In the last 12 months, operating cash flow was 1.53 billion and capital expenditures -760.95 million, giving a free cash flow of 769.71 million.
| Operating Cash Flow | 1.53B |
| Capital Expenditures | -760.95M |
| Depreciation & Amortization | 478.44M |
| Net Borrowing | 128.35M |
| Free Cash Flow | 769.71M |
| FCF Per Share | 1.35 |
Margins
Gross margin is 46.80%, with operating and profit margins of 10.81% and 6.91%.
| Gross Margin | 46.80% |
| Operating Margin | 10.81% |
| Pretax Margin | 9.03% |
| Profit Margin | 6.91% |
| EBITDA Margin | 15.06% |
| EBIT Margin | 10.81% |
| FCF Margin | 6.84% |
Dividends & Yields
This stock pays an annual dividend of 0.75, which amounts to a dividend yield of 2.51%.
| Dividend Per Share | 0.75 |
| Dividend Yield | 2.51% |
| Dividend Growth (YoY) | 14.29% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 61.79% |
| FCF Payout Ratio | 59.76% |
| Buyback Yield | 0.55% |
| Shareholder Yield | 3.05% |
| Earnings Yield | 4.47% |
| FCF Yield | 4.50% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for Winner Medical is 37.56, which is 25.49% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 37.56 |
| Price Target Difference | 25.49% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | 9.08% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
The last stock split was on June 2, 2023. It was a forward split with a ratio of 1.4.
| Last Split Date | Jun 2, 2023 |
| Split Type | Forward |
| Split Ratio | 1.4 |
Scores
Winner Medical has an Altman Z-Score of 3.42 and a Piotroski F-Score of 7.
| Altman Z-Score | 3.42 |
| Piotroski F-Score | 7 |